ResMed Inc.
ResMed Announces Agreement to Sell MatrixCare Business
Summary
ResMed Inc. announced on July 7, 2026, that it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction. The sale is expected to close during the first quarter of fiscal year 2027, subject to regulatory approvals and customary closing conditions. ResMed intends to use the net proceeds to return capital to shareholders and for general corporate purposes. This strategic move aligns with ResMed's focus on high-growth areas in sleep health, breathing health, and connected home-based healthcare.
Profitelligence Alerts
Get alerts for RMD
Be first to know when ResMed Inc. files with the SEC.
Filing Categories
Advertisement
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Official SEC Documents
Advertisement